Back

Clinical performance and safety of a two-lead cardiac resynchronization therapy system with a floating atrial sensing dipole.

7 April 2024 (09:30 - 10:15)
Organised by: Logo
Congress Presentation Part of: Ventricular tachycardia 1 Device Treatment EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Professor Christof Kolb

German Heart Center of Munich, Munich (Germany)

8 More presentations in this session

Presentation thumbnail
Omnipolar mapping and vector mapping in premature ventricular contractions ablation: a comparison with bipolar mapping.
Doctor P. Falzone (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Improving functional substrate delineation for ablation of ventricular tachycardia using high-density electroanatomic mapping and double ventricular extra stimuli protocol
Doctor J. Guichard (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Imaging-derived tissue visualization guides catheter ablation of premature ventricular contractions
Doctor A. Kahle (Duesseldorf, DE)
Abstract Slides Video
Presentation thumbnail
Dynamic voltage mapping of the ventricular tachycardia substrate
Doctor M. Mills (Sheffield, GB)
Abstract Slides Video
Presentation thumbnail
Temporal variability of electromechanical-window negativity in patients with inherited long-QT syndrome or drug-induced QT prolongation: relation to torsades de pointes
Doctor P. Deissler (Essen, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Ventricular tachycardia 1

The Event

Event poster

EHRA 2024

7 April 2024 09:30 CET
You may be interested in
thumbnail
Congress Presentation
The role of atrial pacing support in cardiac resynchronisation therapy in patients without sinus node dysfunction: a non-inferiority randomised trial
thumbnail
Congress Presentation
Two-Lead DX-based versus conventional three-Lead CRT-D: a single centre experience
thumbnail
Congress Presentation
Leadless ultrasound-based cardiac resynchronization system in heart failure results from the SOLVE-CRT randomised sub-study and the primary population patient cohort

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources